FIELD: chemistry.
SUBSTANCE: invention relates to a dual action compound which is characterised by general formula [((S)-N-valeryl-N-{[2'-(lH-tetrazol-5-yl)biphenyl-4-uyl]methyl}valine) ethyl ether (2R,4S)-5-biphenyl-4-yl-4-(3-carboxypropionylamino)-2-methylpentanoic acid]Na1-3·xH2O, in solid form, where x equals 0-3, which is an angiotensin receptor inhibitor and a NEP inhibitor, and can be used to treat hypertension.
EFFECT: high efficiency of using the compound.
19 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSINE RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2459809C2 |
| DOUBLE-ACTION PHARMACEUTICAL COMPOSITIONS OF SUBMOLECULAR STRUCTURE OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | 2008 |
|
RU2493844C2 |
| NEP INHIBITORS FOR TREATMENT OF DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING | 2018 |
|
RU2809222C2 |
| NEP INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING | 2013 |
|
RU2667643C2 |
| GALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2017 |
|
RU2773029C2 |
| SALTS OF 2'-(1H-TETRAZOL-5-YL)-1 AND 1'-BIPHENYL-4-CARBOXALDEHYDE WITH METALS | 2006 |
|
RU2435761C2 |
| VALSARTAN SALTS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR PREPARING SALTS | 2001 |
|
RU2275363C2 |
| APPLICATION OF VALSARTAN OR METABOLITE THEREOF FOR INHIBITION OF THROMBOCYTE AGGREGATION | 2003 |
|
RU2334512C2 |
| TREATMENT OF HYPERTENSION AND/OR PREVENTION AND TREATMENT OF HEART FAILURE IN MAMMAL, RECEIVING ANTICOAGULANT THERAPY | 2011 |
|
RU2564941C2 |
| SUBSTITUTED DERIVATIVES OF BISPHENYL ESTER OF BUTYRIC ACID AS NEP INHIBITORS | 2019 |
|
RU2784522C2 |
